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A B S T R A C T
Soil-transmitted helminths infect 1.5 billion people worldwide. Treatment with anthelminthics is the key in-
tervention but interactions between anthelminthic agents and the gut microbiota have not yet been studied. In
this study, the eﬀects of four anthelminthic drugs and combinations (tribendimidine, tribendimidine plus
ivermectin, tribendimidine plus oxantel-pamoate, and albendazole plus oxantel-pamoate) on the gut microbiota
were assessed. From each hookworm infected adolescent, one stool sample was collected prior to treatment, 24 h
post-treatment and 3 weeks post-treatment, and a total of 144 stool samples were analyzed. The gut bacterial
composition was analyzed using 16S rRNA gene sequencing. Tribendimidine given alone or together with ox-
antel-pamoate, and the combination of albendazole and oxantel pamoate were not associated with any major
changes in the taxonomic composition of the gut microbiota in this population, at both the short-term post-
treatment (24 h) and long-term post-treatment (3 weeks) periods. A high abundance of the bacterial phylum
Bacteroidetes was observed following administration of tribendimidine plus ivermectin 24 h after treatment, due
predominantly to diﬀerence in abundance of the families Prevotellaceae and Candidatus homeothermaceae. This
eﬀect is transient and disappears three weeks after treatment. Higher abundance of Bacteroidetes predicts an
increase in metabolic pathways involved in the synthesis of B vitamins. This study highlights a strong re-
lationship between tribendimidine and ivermectin administration and the gut microbiota and additional studies
assessing the functional aspects as well as potential health-associated outcomes of these interactions are re-
quired.
1. Introduction
Recent estimates suggest that the worldwide prevalence of soil-
transmitted helminths (STHs), including infection with Ascaris lum-
bricoides, Trichuria trichuris and hookworm, is 1.5 billion people (Hotez
et al., 2009; Pullan et al., 2014; Jourdan et al., 2017). The total esti-
mated burden due to STHs is 3.4 million disability-adjusted life years
(GBD, 2015 DALYs and HALE Collaborators, 2016). The symptoms as-
sociated with STH infection are not speciﬁc and are usually more severe
and debilitating in school-aged children and in the elderly. Children
who are chronically infected can display malnutrition and develop-
mental delay while elderly people infected with STHs often display
reduced work-related productivity (Bethony et al., 2006).
Four drugs (albendazole, mebendazole, pyrantel pamoate, levami-
sole) are on the World Health Organization's list of essential medicines
for the treatment of STH infections (WHO, 2002). The two benzimi-
dazoles (albendazole and mebendazole) are most commonly used drugs
in preventive chemotherapy programs (WHO, 2002; Keiser and
Utzinger, 2008; Abou-Zeid et al., 2012). Ivermectin has a broad spec-
trum of activity against diﬀerent parasites ranging from nematodes
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such as Strongyloides stercoralis or A. lumbricoides to ﬁlarial parasites,
and arthropods and even aﬀects the Anopheline vectors of malaria
(Marti et al., 1996; Wen et al., 2008; Grayson et al., 2010; Ōmura and
Crump, 2017). Oxantel has high activity against T. trichuris (Zaman and
Sabapathy, 1975; Horton, 2003; Speich et al., 2014). Finally, tri-
bendimidine has been shown to have a similar spectrum to that of al-
bendazole, and could be an alternative to the latter in case of emer-
gence of benzimidazole resistance (Xiao et al., 2013). There is growing
consensus to use these drugs in combination to increase eﬃcacy and
decrease the risk of drug resistance.
Recent advancements in high-throughput sequencing technologies
enable the characterization of the human microbiome (Turnbaugh
et al., 2007; Arumugam et al., 2011; Human Microbiome Project
Consortium, 2012), which was not possible at the time those drugs were
introduced. Thus, the interactions of these anthelminthic drugs and
drug combinations with the human gut microbiota composed of a
variety of microorganisms, including other eukaryotic parasites, pro-
tozoa, viruses, fungi and most importantly bacteria (Nicholson et al.,
2005; Lozupone et al., 2012; Schneeberger et al., 2016), can now be
studied. Drug-microbiota interactions can modulate the bioavailability
and activity of drugs and hence modulate their eﬃcacy (Nicholson
et al., 2005; Clayton et al., 2009; Wilson and Nicholson, 2009; Cheng
et al., 2013; Maurice et al., 2013). STHs share the same environmental
niche as the gut bacterial microbiota, but potential interactions be-
tween the gut microbiota and anthelminthic agents have not been as-
sessed to date. The aim of this study was to identify potential interac-
tions between these treatments and the non-target microbiota.
2. Methods
2.1. Sample collection and ethics statement
Samples were collected in the framework of a randomized, con-
trolled, single blind, non-inferiority trial in the Agboville district in Côte
d’Ivoire. Hookworm positive adolescents (age 15 to 18), conﬁrmed by
quadruplicate Kato-Katz thick smears, were randomly assigned to four
treatment arms, including tribendimidine (400mg), tribendimidine
(400mg) plus ivermectin (200 μg/kg), tribendimidine (400mg) plus
oxantel pamoate (25mg/kg) and albendazole (400mg) plus oxantel
pamoate (25mg/kg). Details about the study are presented elsewhere
(Moser et al., 2017). From each adolescent, one stool sample was col-
lected prior to treatment, 24 h post-treatment and 3 weeks post-treat-
ment, and a total of 144 stool samples were analyzed (Table 1).
Ethical approval was obtained from the Comité National d’Ethique
et de la Recherche in Côte d’Ivoire (083/MSHP/CNER-kp) and the
Ethics Committee of North-western and Central Switzerland (EKNZ
UBE-15/35). The trial was registered with ISRCTN (number 14373201).
2.2. Sample collection
For DNA isolation, 150–250mg of stool sample was diluted in
500 μl of AVL buﬀer (Qiagen, Darmstadt, Germany) and subsequently
homogenized using a soil-grinding SK38 kit on the Precellys 24 system
(Bertin Technologies, Saint-Quentin, France). Homogenized samples
were further extracted on a Magna Pure 96 system (Roche, Basel,
Switzerland) using the DNA and Viral NA Large Volume kit (Roche,
Basel, Switzerland) according to the manufacturers' protocol.
2.3. 16S amplicon PCR
2.5 μl of isolated DNA was used to perform ampliﬁcation of the V3-
V4 region using the following primer pair:
Forward primer= 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGA-
CAGCCTACGGGNGGCWGCAG
Reverse primer= 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGA-
CAGGACTACHVGGGTATCTAATCC
Table 1
Summary of volunteers investigated in this study. From each adolescent of each of the four treatments, a sample was collected before, 24 h after and 3 weeks after
treatment. EPG=Hookworm eggs per gram of stool, FU= follow-up.
ID Samples EPG (baseline) EPG (FU) ID Samples EPG (baseline) EPG (FU)
Treatment arm 1 Treatment arm 2
P- 5 D6, E6, F6 318 426 P- 6 D8, E7, F7 144 0
P- 7 D9, E8, F8 30 0 P- 17 D21, E18, F18 12 0
P- 9 D11, E10, F10 96 132 P- 19 D23, E20, F20 84 0
P- 10 D12, E11, F11 36 228 P- 23 D27, E24, F24 1002 0
P- 11 D13, E12, F12 198 108 P- 27 D31, E28, F28 72 0
P- 14 D16, E15, F15 78 0 P- 33 D42, E30, F30 534 0
P- 22 D26, E23, F23 450 78 P- 34 D43, E31, F31 78 0
P- 26 D30, E27, F27 36 0 P- 35 D44, E44, F44 42 0
P- 29 D34, E40, F40 102 6 P- 43 D78, E45, F45 30 0
P- 32 D39, E43, F43 336 54 P- 46 D91, E37, F37 18 0
P- 38 D55, E33, F33 78 0 P- 48 D95, E34, F34 4740 0
P- 41 D76, E38, F38 240 0
Treatment arm 3 Treatment arm 4
P- 2 D3, E3, F3 450 66 P- 1 D1, E1, F1 42 36
P- 3 D4, E4, F4 966 0 P- 4 D5, E5, F5 96 288
P- 8 D10, E9, F9 186 210 P- 15 D18, E16, F16 534 0
P- 12 D14, E13, F13 126 0 P- 20 D24, E21, F21 66 0
P- 13 D15, E14, F14 492 108 P- 21 D25, E22, F22 204 90
P- 16 D20, E17, F17 630 516 P- 24 D28, E25, F25 426 24
P- 18 D22, E19, F19 696 282 P- 25 D29, E26, F26 72 108
P- 28 D33, E29, F29 1824 0 P- 31 D37, E41, F41 222 204
P- 30 D35, E42, F42 1698 1302 P- 37 D52, E46, F46 258 48
P- 36 D50, E47, F47 222 24 P- 40 D62, E36, F36 912 0
P- 39 D58, E48, F48 60 12 P- 42 D77, E39, F39 582 0
P- 44 D79, E2, F2 270 0 P- 47 D94, E32, F32 2580 60
P- 45 D86, E35, F35 168 0
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The polymerase chain reaction (PCR) was performed in 25 μl reac-
tion volumes using the 2X KAPA HiFi HotStar ReadyMix (KAPA
Biosystems; Boston, MA, USA). The thermocycler was set as follows:
95 °C for 3min, 25 cycles of 95 °C (30 s), 55 °C (30 s) and 72 °C (30 s),
one additional step at 72 °C for 5min and ﬁnally set on hold indeﬁnitely
at 4 °C. The quality of the ampliﬁed product was controlled visually on
a 1% agarose gel. The amplicons were puriﬁed using an AMPure XP
beads (Beckman-Coulter; Fullerton, CA, USA) protocol.
2.4. Sequencing
We used a Nextera XT Index kit (Illumina, San Diego, CA, United
States of America) to perform the index PCR and generate barcoded
pools of 96 samples. The ampliﬁcation reaction was conducted on a
thermocycler under the following condition: 95 °C for 3 min, 20 cycles
of 95 °C for 30 s, 55 °C for 30 s, 72 °C for 30 s, one additional step at
72 °C for 5 min and a ﬁnal step at 4 °C until further processing.
Amplicons were cleaned with AMPure XP beads according to Illuminas'
library preparation guide. The quality of the product was assessed using
a 1% agarose gel and the quantiﬁcation was performed using a Qubit
Fluorimeter (Life Technologies, Carlsbad, CA, United States of America)
and the corresponding High-sensitivity DNA assays (Life Technologies,
USA). The 96 amplicon samples were pooled together in an equimolar
way and loaded on a cartridge on the Illumina Miseq sequencing
platform (Illumina, USA). We used V3 reagents (2*300bp) (Illumina,
USA) for this experiment in 2*300 base pair mode.
2.5. Data processing and statistical analysis
Raw Fastq ﬁles were ﬁltered using a quality score (Phred) above
Q20. Filtered reads were fed in the QIIME pipeline (Caporaso et al.,
2010) v 1.9.1, which was conﬁgured for standard OTU picking (closed
reference, Greengenes database v.13_8). Shannon diversity index was
computed with QIIME using a rarefaction depth of 19500 sequences
and principal component analysis (PCA) plots were generated with the
STAMP statistical analysis package (Parks et al., 2014) using Euclidean
distance matrices. Taxonomic proﬁles were further analyzed with the
PICRUSt suite (Langille et al., 2013), in order to predict the functional
content of the gut microbiota based on the abundance of 16S rRNA
genes. To compare groups (treatment arms), we performed an analysis
of variance using the STAMP software (Parks et al., 2014), both for
taxonomical and functional proﬁles. Benjamini-Hochberg correction
(Benjamini and Hochberg, 1995) was applied to the uncorrected sta-
tistics, to control for multiple testing bias. Statistical signiﬁcance is
reached with a corrected p-value (q-value) below 0.1.
Fig. 1. Overall diversity comparison of taxonomic composition at the phylum level, stratiﬁed by treatment arm. TA1=Tribendimidine;
TA2=Tribendimidine plus ivermectin; TA3=Tribendimidine plus oxantel pamoate; TA4=Albendazole plus oxantel pamoate. Panel A: pre-treatment. Panel B:
24 h post-treatment. Panel C: 3 weeks post-treatment. Panel D shows the Shannon diversity index at each time point. h= hours; w=weeks.
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3. Results
3.1. Overall comparison of the taxonomic composition between treatment
arms
Pre-processing, including ﬁltering and denoising of the sequence
datasets resulted in the analysis of a total of 2,311,784 high quality
reads for the 48 pre-treatment samples (median=55,000), 2,261,185
reads for the 48 samples collected 24 h after treatment
(median=56,826), and 2,580,596 ﬁltered reads for the 48 samples
collected in the follow-up period of 3 weeks (median= 59,889). We
compared the overall microbiota diversity of all samples, grouped by
treatment arm, using a principal component analysis and the Shannon
diversity index, as shown in Fig. 1. Complete taxonomic proﬁles stra-
tiﬁed by treatment arm are shown in Supplementary Fig. 1.
Treatment groups were not associated with signiﬁcant diﬀerences in
taxonomic composition or Shannon diversity at any time-point.
Although two samples (P-3 and P-8) from treatment arm 3 (tribendi-
midine plus oxantel pamoate) diﬀered signiﬁcantly from the rest of the
population before treatment, there was no observable diﬀerence in gut
bacterial composition of these two patients both at 24 h post-treatment
and 3 weeks post treatment.
At 24 h after drug administration, the principal component analysis
showed a homogeneous population and the SDI across all treatment
arms was not signiﬁcantly diﬀerent. However, there was a noticeable
spread (∼0.35–0.2) of samples belonging to treatment arm 2 over
component 1 (x-axis), while samples from this group all clustered
tightly before treatment (within coordinates −0.1 and ∼0.1 on both
axis).
Finally, the observation of a generally homogeneous bacterial
composition of the gut microbiota at the phylum level in the studied
population was conﬁrmed in the samples collected 3 weeks after ad-
ministration of the treatments. According to the PCA, the sample col-
lected from patient 39 diﬀered from the rest of the population, at this
sampling time. The SDI for this sample was low (SDI= 1.72) compared
to the rest of the group.
3.2. Diﬀerences in taxonomic composition after administration of the four
treatments
In order to assess the potential eﬀect of each drug/drug combination
tested in this study on the gut microbiota, we compared abundance
means of each bacterial taxon between groups, at diﬀerent taxonomic
levels (phylum and family). At baseline, there was no phylum which
was diﬀerentially abundant between the four treatment arms. 24 h after
treatment, there was a signiﬁcantly higher abundance (q-value < 0.1)
of species from the Bacteroidetes phylum in samples from treatment arm
2. The relative abundance of Bacteroidetes was greater in treatment arm
2 than all other groups 24 h after treatment, but not at baseline nor at 3
weeks.
In order to quantify the degree of variation of Bacteroidetes over
time, we compared those from pre-to 24 h post-treatment samples and
those from 24 h post-to 3 weeks post-treatment samples, as shown in
Fig. 2.
In order to further characterize potential drug-bacteria interactions,
we screened lower taxonomic levels and found two families, which
follow a similar abundance pattern (A) to that of Bacteroidetes
(ATA2>ATA1=ATA3=ATA4), namely S24_7 (recently renamed to
Candidatus homothermaceae (Ormerod et al., 2016),) and Prevotellaceae.
However, for both families, the signiﬁcance for inter-group diﬀerence
was not reached (q-value > 0.1).
3.3. Prediction of metabolic pathways
In order to highlight possible interactions, we compared the pre-
dicted abundance of metabolic pathways obtained with PICRUSt be-
tween the four treatment arms at each sampling time (Fig. 3).
In samples collected at baseline, the abundance of sequences related
to biotin metabolism, folate, and N-glycan biosynthesis was the same
across all treatment groups. The situation changed 24 h after treatment
when these metabolic pathways became signiﬁcantly more abundant in
the tribendimidine-ivermectin treatment arm (q-values= 0.047, 0.016,
and 0.038, for biotin metabolism, folate biosynthesis, and N-glycan
biosynthesis, respectively). The abundance pattern was the same for
each of the three pathways, the highest abundance being associated to
treatment with tribendimidine in combination with ivermectin (treat-
ment arm 2) and being lower for the three other groups. The situation
after 3 weeks was similar to pre-treatment, and no diﬀerentially
abundant pathway could be identiﬁed.
4. Discussion
There is a growing interest in associations between the human mi-
crobiome and drug therapy, which has been called “pharmacomicro-
biomics” (Rizkallah et al., 2010; Wang et al., 2011; Klatt et al., 2017;
Wilson and Nicholson, 2017). This study is the ﬁrst investigating eﬀects
of diﬀerent anthelminthic drugs and their combinations on the human
gut microbiota of adolescents infected with hookworms in a tropical
setting.
Several studies have shown that the eﬀects of various parasitic in-
fections on the gut microbiota are relatively modest (Cantacessi et al.,
2014; Kay et al., 2015; Schneeberger et al., 2018), yet, there is only
scarce information about the impact, direct (= drug eﬀect on bacterial
composition) or indirect (= change in bacterial composition is due to
clearance of the worm), of drugs used to treat parasitic infections on the
gut microbiota. Cross-reaction of drugs designed to target eukaryotic
parasites between the gut microbiota and various treatments (e.g. anti-
cancerous drugs) has been shown (Alexander et al., 2017; Roy and
Trinchieri, 2017), and given the fact STHs and gut bacteria share the
same environment these eﬀects are possible for anthelminthic drugs as
well.
Our analyses indicate that tribendimidine given alone or together
with oxantel pamoate, and the combination of albendazole and oxantel
Fig. 2. Box plot showing the abundance variation of the phylum
Bacteroidetes. This plot summarizes variations of abundance of Bacteroidetes
between two sampling times (from pre-treatment to 24 h post-treatment and
24 h to 3 weeks post-treatment), by treatment arm. Treatment arm
1=Tribendimidine; Treatment arm 2=Tribendimidine plus ivermectin;
Treatment arm 3=Tribendimidine plus oxantel pamoate; Treatment arm
4=Albendazole plus oxantel pamoate.
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pamoate is not associated with any major changes in the taxonomic
composition of the gut microbiota in this population, at both the short-
term post-treatment (24 h) and long-term post-treatment (3 weeks)
periods. However, treatment with tribendimidine in combination with
ivermectin was found to be associated with shifts in the relative
abundance of Bacteroidetes. This phylum increased in relative abun-
dance in the ﬁrst 24 h post-administration and decreased over the 3
weeks post-treatment. Within the Bacteroidetes phylum, two bacteria
families, Prevotellaceae and Candidatus Homeothermaceae (former S24_7
(Ormerod et al., 2016)), accounted for most of the variation observed in
the abundance of Bacteroidetes.
We assessed the potential metabolic signiﬁcance of this taxonomic
shift using PICRUSt prediction, which accurately infers metabolic gene
content from taxonomic composition (Lindgreen et al., 2016). Of all
Fig. 3. Box plot comparing the abundance of predicted metabolic pathways at the diﬀerent sampling times. TA1=Tribendimidine; TA2=Tribendimidine plus
ivermectin; TA3=Tribendimidine plus oxantel pamoate; TA4=Albendazole plus oxantel pamoate. Panel A shows the abundance of biotin metabolism, folate
biosynthesis and N-glycan biosynthesis pathways before treatment, by treatment arm. Panel B shows the abundance of the three metabolic pathways, 24 h after
administration of treatment. Panel C highlights the abundance of the three metabolic pathways, 3 weeks after administration of treatment. Signiﬁcance is achieved
with a q-value<0.1. q-values are shown only for comparisons which are signiﬁcantly diﬀerent.
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predicted metabolic pathways, three were signiﬁcantly more abundant
in samples from treatment arm 2, namely, biotin metabolism, folate
biosynthesis, and N-glycan biosynthesis, and all are involved at some
point in the biosynthesis of B vitamins. While the statistical proof of
higher abundance of Prevotellaceae and Candidatus Homeothermaceae in
patients from treatment arm 2 (tribendimidine plus ivermectin) is
somewhat weaker to that of Bacteroidetes, it has been shown that both
groups present characteristics highly relevant to each of the three dif-
ferentially abundant metabolic pathways. Indeed, and while acknowl-
edging that it does not encompass the complete range of their activities
in the gut, members from the Prevotellaceae family almost ubiquitously
harbor the genes associated with B vitamin biosynthesis (Magnúsdóttir
et al., 2015). Similarly, one of the purposes of Candidatus Home-
othermaceae in the gut of mammals is to regulate the synthesis of B
vitamins (Ormerod et al., 2016). Of note, a possible cause for the lack of
statistical power for ﬁndings observed in our study for these two taxa is
the intrinsically weak taxonomic resolution of 16S rRNA gene identi-
ﬁcation, which frequently does not allow categorizing sequences at
lower taxonomic levels, in this case, the family level. High level of
biotin, or vitamin B7, in rat livers, has been associated with decreased
absorption of orally administered vitamin B12 (Puddu and Marchetti,
1965). For folate (vitamin B9), decreased concentrations in combina-
tions with low B12 levels have been associated with various symptoms,
including anemia (Morris et al., 2007; Selhub et al., 2009), a common
consequence of ivermectin administration (Ndyomugyenyi et al.,
2008). However, in order to validate these observations and to under-
stand these interactions in detail, additional studies investigating other
parameters (e.g. monitoring of B vitamins levels after treatment) and
tests with higher taxonomic resolution (e.g. strain identiﬁcation with
shotgun metagenomics) are required.
This study has limitations. Indeed, while the study design in its
current form enables the identiﬁcation of signiﬁcant diﬀerences in the
composition of the gut microbiota between diﬀerent treatment groups,
it does not allow distinguishing between direct or indirect eﬀects.
Future studies might be considered including treatment of uninfected
patients and patients who received a placebo, although this might be
challenging from an ethical point of view. However, it is worth high-
lighting that the observed eﬀects (higher abundance of Bacteroidetes
and speciﬁc metabolic pathways) are distributed homogeneously across
all samples analyzed from the tribendimidine-ivermectin group, except
for one sample measured 24 h post-treatment. Additionally, stable
abundance of Bacteroidetes and the metabolic pathways is observed
homogeneously across all samples from the other treatment groups,
except for two samples. Both facts support the hypothesis of a re-
compositional event triggered by the administration of tribendimidine
plus ivermectin and rule out observed eﬀects driven mainly by random
outlying samples.
5. Conclusion
In conclusion, our study revealed several key ﬁndings of anti-
helminthic drugs/microbiota interactions. Tribendimidine, tribendimi-
dine plus oxantel pamoate and albendazole plus oxantel-pamoate do
not cause microbiome-speciﬁc eﬀects and hence are unlikely to cause
variability in response. On the other hand, treatment with a combina-
tion of tribendimidine and ivermectin triggers a re-compositional event
of the gut microbiota, which was not observed for the other treatments
studied. Moreover, a higher abundance of Bacteroidetes, and to some
extent, of bacteria from the Prevotellaceae and Candidatus
Homeothermaceae families as well as an overrepresentation of metabolic
pathways related to B vitamins biosynthesis, was observed in patients
treated with tribendimidine and ivermectin, 24 h after treatment.
Importantly, the observed eﬀects are transient as they disappear within
three weeks after administration of this anthelminthic treatment.
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